DK2049671T3 - Regulatoriske nukleinsyreelementer - Google Patents

Regulatoriske nukleinsyreelementer

Info

Publication number
DK2049671T3
DK2049671T3 DK07730192.7T DK07730192T DK2049671T3 DK 2049671 T3 DK2049671 T3 DK 2049671T3 DK 07730192 T DK07730192 T DK 07730192T DK 2049671 T3 DK2049671 T3 DK 2049671T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
regulatory nucleic
acid elements
elements
regulatory
Prior art date
Application number
DK07730192.7T
Other languages
English (en)
Inventor
Barbara Enenkel
Kerstin Sautter
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK2049671T3 publication Critical patent/DK2049671T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07730192.7T 2006-07-26 2007-06-15 Regulatoriske nukleinsyreelementer DK2049671T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117862 2006-07-26
PCT/EP2007/055954 WO2008012142A1 (de) 2006-07-26 2007-06-15 Regulatorische nukleinsäureelemente

Publications (1)

Publication Number Publication Date
DK2049671T3 true DK2049671T3 (da) 2013-04-08

Family

ID=37441548

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07730192.7T DK2049671T3 (da) 2006-07-26 2007-06-15 Regulatoriske nukleinsyreelementer

Country Status (22)

Country Link
US (3) US20080124760A1 (da)
EP (1) EP2049671B1 (da)
JP (1) JP5270544B2 (da)
KR (1) KR101485853B1 (da)
CN (1) CN101517085B (da)
AR (1) AR061472A1 (da)
AU (1) AU2007278368B2 (da)
BR (1) BRPI0714594A2 (da)
CA (1) CA2658595C (da)
CY (1) CY1113711T1 (da)
DK (1) DK2049671T3 (da)
EA (1) EA016880B1 (da)
ES (1) ES2401654T3 (da)
IL (1) IL196676A0 (da)
MX (1) MX2009000781A (da)
NO (1) NO20090057L (da)
NZ (1) NZ575115A (da)
PL (1) PL2049671T3 (da)
PT (1) PT2049671E (da)
SI (1) SI2049671T1 (da)
TW (1) TW200815591A (da)
WO (1) WO2008012142A1 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
EP2697375B1 (en) 2011-04-13 2017-10-18 National Research Council of Canada Expression system with scaffold attachment region (sar) element from interferon 2
EP2771031B1 (en) 2011-10-28 2018-04-18 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
SG10201700169PA (en) * 2011-12-22 2017-02-27 Hoffmann La Roche Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
EP2807188B1 (en) 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
EP3116906A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2016126747A1 (en) 2015-02-02 2016-08-11 Meiragtx Uk Limited Regulation of gene expression by aptamer-mediated modulation of alternative splicing
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
KR102581734B1 (ko) 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법
MA51223A (fr) 2017-11-29 2020-10-07 Prothena Biosciences Ltd Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
SG11202104549TA (en) 2018-11-08 2021-05-28 Prothena Biosciences Ltd Antibodies recognizing tau
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
AU2021297540A1 (en) 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
WO2022226005A1 (en) * 2021-04-21 2022-10-27 Janssen Biotech, Inc. Materials and methods for improved phosphotransferases
CN122070299A (zh) 2023-09-15 2026-05-19 普罗塞纳生物科学有限公司 细胞穿透剂及其用途
WO2025059486A1 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Anti-tdp-43 antibodies and uses thereof
EP4777522A2 (en) 2023-09-15 2026-07-22 Prothena Platform Technologies Limited Methods, compositions, and kits including cell-penetrating agents
WO2025059487A2 (en) 2023-09-15 2025-03-20 Othair Prothena Limited Cell penetrating agents and uses thereof
WO2026005490A1 (ko) * 2024-06-25 2026-01-02 서울대학교산학협력단 목적 유전자의 발현 조절을 위한 인공 핵산 및 이를 이용한 다수 유전자의 발현 조절 시스템

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
US5786166A (en) 1991-10-25 1998-07-28 University Of Tennessee Research Corporation Methods for determining effects of a compound on the activity of bacterial periplasmic oxidoreductase enzymes
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
DE19539493A1 (de) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
NZ330926A (en) 1996-01-11 1999-11-29 Immunex Corp Expression augmenting sequence elements (ease) for eukaryotic expression systems
WO2000034326A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof
WO2000034318A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof
WO2000034319A1 (en) 1998-12-11 2000-06-15 Clontech Laboratories, Inc. Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof
AUPP967999A0 (en) * 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
DE60025829T2 (de) 1999-07-12 2006-11-02 Genentech, Inc., South San Francisco Expressionsvektoren und anwendungsmethoden
AU783767B2 (en) 1999-10-14 2005-12-01 Takara Bio Usa, Inc. Anthozoa derived chromophores/fluorophores and methods for using the same
WO2002081677A2 (en) 2001-04-05 2002-10-17 Ml Laboratories Plc Improved gene expression
DE60237048D1 (de) 2001-07-04 2010-08-26 Chromagenics Bv DNS-Sequenzen mit Anti-Repressor-Aktivität
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
DE50308030D1 (de) 2002-11-29 2007-10-04 Boehringer Ingelheim Pharma Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
DE10256083A1 (de) * 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen

Also Published As

Publication number Publication date
EA200900212A1 (ru) 2009-10-30
WO2008012142A1 (de) 2008-01-31
EA016880B1 (ru) 2012-08-30
ES2401654T3 (es) 2013-04-23
JP5270544B2 (ja) 2013-08-21
US20080124760A1 (en) 2008-05-29
NO20090057L (no) 2009-02-16
PL2049671T3 (pl) 2013-05-31
US9045776B2 (en) 2015-06-02
TW200815591A (en) 2008-04-01
IL196676A0 (en) 2011-08-01
KR20090046887A (ko) 2009-05-11
HK1134107A1 (en) 2010-04-16
CN101517085A (zh) 2009-08-26
CA2658595A1 (en) 2008-01-31
EP2049671B1 (de) 2012-12-19
US20150337333A1 (en) 2015-11-26
US9708626B2 (en) 2017-07-18
AU2007278368A1 (en) 2008-01-31
JP2009544293A (ja) 2009-12-17
CA2658595C (en) 2016-05-31
BRPI0714594A2 (pt) 2013-02-19
AU2007278368B2 (en) 2013-12-19
AR061472A1 (es) 2008-08-27
PT2049671E (pt) 2013-01-24
MX2009000781A (es) 2009-01-29
EP2049671A1 (de) 2009-04-22
SI2049671T1 (sl) 2013-04-30
CY1113711T1 (el) 2016-06-22
US20100311121A1 (en) 2010-12-09
CN101517085B (zh) 2013-08-07
NZ575115A (en) 2011-10-28
KR101485853B1 (ko) 2015-01-23

Similar Documents

Publication Publication Date Title
NL301077I2 (nl) isatuximab
DK1984502T3 (da) Nukleinsyre
IL196676A0 (en) Regulatory nucleic acid elements
DK2129797T3 (da) Nukleinsyrepåvisning
BRPI0718796A2 (pt) Nucleotídeo
EP2051924A4 (en) ELEVATOR SYSTEM
DK2203551T3 (da) Bifidobakterieart
AT504580A3 (de) Scan-einrichtung
FI20060588A0 (fi) Hissijärjestelmä
FI20060511A0 (fi) Hissijärjestelmä
DE502007005526D1 (de) Pipettiervorrichtung
DE502007001629D1 (de) Rfahren
ATE546437T1 (de) Aminomethyl-4-imidazole
EP2013130A4 (en) ELEVATOR SYSTEM
DE502007000218D1 (de) nsetzungen
FI20060214A0 (fi) Hissijärjestelmä
DE602007013849D1 (de) Mikroreaktor
DK1994062T3 (da) Aryl/alkyl-vinylsulfonhyaluronsyrederivater
DE502007000361D1 (de) Stanznieteinheit
DK1986928T3 (da) Palle
DE112007003147A5 (de) Rohr-Biegevorrichtung
DE602007009334D1 (de) Garnerwärmungsvorrichtung
FI20060963A0 (fi) Hissijärjestelmä
DE502007001652D1 (de) Notöltank
DK2054074T3 (da) Modificeret erythropoietin